Insulin resistance in nonalcoholic steatohepatitis: Necessary but not sufficient-death of a dogma from analysis of therapeutic studies?

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 279-289

  Lonardo, Amedeo ^a,b   Bellentani, Stefano ^c   Ratziu, Vlad ^d   Loria, Paola ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

^c AUSL Modena   (Italy)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

electron microscopy; fibrosis; histology; history of medicine; mitochondria; NAFLD; NASH; pathogenesis; randomized controlled trial; treatment

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETAINE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN; TETRAHYDROLIPSTATIN; TROGLITAZONE; URSODEOXYCHOLIC ACID; VALSARTAN;

DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER BIOPSY; LOW CALORY DIET; MICROSCOPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; MICE; MITOCHONDRIA, LIVER; MITOCHONDRIAL DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN E;

EID: 79954548597     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.19     Document Type: Review

References (66)

1. Loria P, Adinolf LE, Bellentani S et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig. Liver Dis. 42, 272-282 (2010).
2. Caldwell S, Ikura Y, Dias D et al. Hepatocellular ballooning in NASH. J. Hepatol. 53, 719-723 (2010).
3. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31, 430-434 (1999). (Pubitemid 29408724)
4. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192 (2001). (Pubitemid 32246672)
5. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 8(Suppl. 1), S4-S8 (2009).
6. Caldwell S, Argo C The natural history of non-alcoholic fatty liver disease. Dig Dis. 28(1), 162-168 (2010).
7. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fbrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51, 371-379 (2009).
8. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434-438 (1980). (Pubitemid 10057164)
9. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL Special Conference. J. Hepatol. 53, 372-384 (2010).
10. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 30, 795-808 (2010).
11. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52, 79-104 (2010).
12. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450-455 (1999). (Pubitemid 29528333)
13. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin. Nutr. 18, 353-358 (1999). (Pubitemid 30032243)
14. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Dig Dis. 17, 80-89 (1999). (Pubitemid 29463095)
15. Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Rev. Endocrinol. Metab. 5, 403-423 (2010).
16. Martínez de Morentin PB, Varela L, Fernø J, Nogueiras R, Diéguez C, López M. Hypothalamic lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta 1801, 350-361 (2010).
17. Day CP., James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 114, 842-845 (1998). (Pubitemid 28160420)
18. Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 5(2), 253-263 (2011).
19. Vos MB, McClain CJ. Fructose takes a toll. Hepatology 50, 1004-1006 (2009).
20. Enjoji M, Nakamuta M. Is the control of dietary cholesterol intake suffciently effective to ameliorate nonalcoholic fatty liver disease? World J. Gastroenterol. 16, 800-803 (2010).
21. Maher JJ. Trunk fat as a determinant of liver disease. Gastroenterology 138, 1244-1246 (2010).
22. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory ftness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130, 2023-2030 (2006) (Pubitemid 43816951)
23. Erratum in: Gastroenterology 132, 466 (2007).
24. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 52, 370-381 (2010).
25. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev. Gastroenterol. Hepatol. 6, 236-247 (2009).
26. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline defciency. Gastroenterology 140(3), 976-986 (2011).
27. Verdam FJ, Rensen SS, Driessen A, Greve JW, Buurman WA. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 45(2), 149-152 (2011).
28. Aigner E, Strasser M, Haufe H et al. A role for low hepatic copper concentrations in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 105, 1978-1985 (2010).
29. Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J. Clin. Gastroenterol. 40, 930-935 (2006). (Pubitemid 44690769)
30. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol. 50, 1029-1034 (2009).
31. Yoneda M, Nozaki Y, Endo H et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis. Sci. 55, 808-814 (2010).
32. Ratziu V, Giral P, Jacqueminet S et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 135, 100-110 (2008). (Pubitemid 351916703)
33. Nobili V, Manco M, Devito R et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48, 119-128 (2008). (Pubitemid 351975537)
34. Nobili V, Manco M, Ciampalini P et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin. Ther. 30, 1168-1176 (2008). (Pubitemid 351978124)
35. Aithal GP, Thomas JA, Kaye PV et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135, 1176-1184 (2008).
36. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49, 80-86 (2009).
37. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J. Clin. Gastroenterol. 43, 990-994 (2009).
38. Gastaldelli A, Harrison SA, Belfort-Aguilar R et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50, 1087-1093 (2009).
39. Vilar Gomez E, Rodriguez De Miranda A et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 30, 999-1009 (2009).
40. Abdelmalek MF, Sanderson SO, Angulo P et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50, 1818-1826 (2009).
41. Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121-129 (2010).
42. Ratziu V, Charlotte F, Bernhardt C et al. Long-term effcacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial. Hepatology 51, 445-453 (2010).
43. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675-1685 (2010).
44. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fbrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98, 2485-2490 (2003). (Pubitemid 37448761)
45. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39, 770-778 (2004). (Pubitemid 38337657)
46. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355,2297-2307 (2006). (Pubitemid 44837778)
47. Dufour JF, Oneta CM, Gonvers JJ et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 4, 1537-1543 (2006). (Pubitemid 44880031)
48. Zelber-Sagi S, Kessler A, Brazowsky E et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4, 639-644 (2006).
49. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15, 942-954 (2009).
50. Leuschner UF, Lindenthal B, Herrmann G et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52, 472-479 (2010).
51. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96, 519-525 (2001).
52. García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuán T, Martínez MA, Muñoz-Yagüe T, Solís-Herruzo JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 46, 414-423 (2007). (Pubitemid 47344776)
53. Caldwell SH, Patrie JT, Brunt EM et al. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology 46, 1101-1107 (2007). (Pubitemid 350144774)
54. Nocito A, Dahm F, Jochum W et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 133, 608-618 (2007). (Pubitemid 47187345)
55. Zaldivar MM, Pauels K, von Hundelshausen P et al. CXC chemokine ligand 4 (CXCL4) is a platelet-derived mediator of experimental liver fbrosis. Hepatology 51, 1345-1353 (2010).
56. Wouters K, van Gorp PJ, Bieghs V et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic infammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474-486 (2008).
57. Wei Y, Clark SE, Thyfault JP et al. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am. J. Pathol. 174, 1329-1337 (2009).
58. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 52, 2206-2215 (2010).
59. Lavine JE, Schwimmer JB, Molleston JP et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp. Clin. Trials 31, 62-70 (2010).
60. Lavine JE, Schwimmer JB, Molleston JP et al. Vitamin E, metformin or placebo for treatment of nonalcoholic fatty liver disease in children. Hepatology 52(Suppl. 1), A374-A375 (2010).
61. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38, 1008-1017 (2003). (Pubitemid 37221684)
62. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev. CD007340 (2010).
63. Furuya CK Jr, De Oliveira CP, de Mello ES et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary fndings after 2 years. J. Gastroenterol. Hepatol. 22, 510-514 (2007). (Pubitemid 46434992)
64. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis, a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467-2474 (1999). (Pubitemid 29420675)
65. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39, 188-196 (2004). (Pubitemid 38461481)
66. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005). (Pubitemid 40770284)